Related Experiment Video

Updated: Feb 12, 2026

Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients
09:16

Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients

Published on: February 28, 2018

8.1K

Blockade of the renin-angiotensin-aldosterone system in patients with arrhythmogenic right ventricular dysplasia: A

Elodie Morel1, Ab Waheed Manati2, Patrice Nony3

  • 1Service Rythmologie, Hôpital Cardiologique Louis Pradel, Hospices Civils de Lyon, Lyon, France.

Clinical Cardiology
|March 26, 2018
PubMed

Insights

The BRAVE study investigates ramipril for arrhythmogenic right ventricular dysplasia (ARVD), aiming to reduce right ventricular deterioration and arrhythmia. This research seeks a treatment to prevent disease progression and improve patient quality of life.

Area of Science:

  • Cardiology
  • Pharmacology
  • Medical Research

Background:

  • Arrhythmogenic right ventricular dysplasia (ARVD) is a rare cardiomyopathy causing fatty and fibrous tissue replacement in the right ventricle.
  • Current ARVD treatments are empirical, focusing on arrhythmia management rather than disease modification.
  • No antifibrotic therapies have been validated for ARVD, highlighting a critical unmet need.

Purpose of the Study:

  • To evaluate the efficacy of ramipril, an ACE inhibitor, in mitigating ventricular myocardial remodeling and arrhythmia burden in ARVD patients.
  • To assess ramipril's potential to prevent the deterioration of right ventricular function in ARVD.
  • To explore the antifibrotic effects of ramipril in the context of ARVD.

Main Methods:

  • The BRAVE study is a phase 4, double-blind, randomized, multicenter trial.
  • 120 ARVD patients will be randomized to receive either ramipril or a placebo for 3 years.
  • Co-primary endpoints include changes in telediastolic right ventricular volume (via MRI) and arrhythmia burden over 3 years.

Main Results:

  • This section is to be filled after the study's completion.
  • Expected outcomes include reduced right and/or left ventricular deterioration and a decreased arrhythmia burden in the ramipril group.
  • Anticipated benefits encompass improved quality of life and reduced hospitalizations for ARVD patients.

Conclusions:

  • The BRAVE study aims to establish ramipril as a disease-modifying therapy for ARVD.
  • Positive results could lead to a novel treatment strategy for ARVD, addressing the current lack of disease-specific interventions.
  • This research may significantly improve long-term outcomes for patients suffering from this debilitating cardiomyopathy.

Keywords:
Arrhythmia/AllCardiomyopathyRemodeling/CardiovascularSudden Death

More Related Videos

Patient-specific Modeling of the Heart: Estimation of Ventricular Fiber Orientations12:09

Patient-specific Modeling of the Heart: Estimation of Ventricular Fiber Orientations

Published on: January 8, 2013

14.1K
Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers04:09

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers

Published on: March 3, 2023

3.8K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K
Blind Procedures02:07

Blind Procedures

Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
13.7K
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
36.2K
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

Body:Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to...
256
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
164
Neuromuscular Junction And Blockade01:29

Neuromuscular Junction And Blockade

The site of chemical communication between a motor neuron and a muscle fiber is called the neuromuscular junction (NMJ). The end of the motor neuron at the NMJ divides into a cluster of synaptic end bulbs. The cytoplasm of these bulbs consists of synaptic vesicles enclosing acetylcholine molecules, the principal neurotransmitter released at the NMJ. The region opposite the synaptic bulb that ends in the muscle fiber is called the motor end plate, which has acetylcholine receptors. Within the...
5.1K